Related Experiment Video
Updated: Jul 30, 2025
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Exploring the Complex Relationship between Diabetes and Cardiovascular Complications: Understanding Diabetic
Nilanjan Ghosh1, Leena Chacko2, Hiranmoy Bhattacharya3
1Molecular Pharmacology Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India.
Insights
Diabetes mellitus (DM) leads to diabetic cardiomyopathy (DCM), causing heart failure through complex pathways. Emerging therapies like GLP-1 analogues and SGLT-2 inhibitors show promise for cardiovascular outcomes in diabetic patients.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Syndrome
Background:
- Diabetes mellitus (DM) significantly increases cardiovascular complications, notably heart failure.
- Diabetic cardiomyopathy (DCM) arises from complex metabolic and molecular pathways unique to diabetes.
- DM is a cardio-renal metabolic syndrome associated with severe vascular risk factors.
Purpose of the Study:
- To elucidate the pathophysiological, metabolic, and molecular mechanisms driving DCM development.
- To detail the structural and functional cardiac alterations in DCM.
- To review potential future therapeutic strategies for DCM.
Main Methods:
- Review of pathophysiological pathways in diabetic cardiomyopathy.
- Analysis of metabolic and molecular underpinnings of DCM.
- Examination of cardiovascular outcomes associated with novel diabetes pharmacotherapies.
Main Results:
- DCM involves structural changes like hypertrophy and fibrosis, and functional decline from diastolic to systolic dysfunction.
- Glucagon-like peptide-1 (GLP-1) analogues and sodium-glucose cotransporter-2 (SGLT-2) inhibitors demonstrate significant cardiovascular benefits.
- These therapies improve cardiac contractile bioenergetics in diabetic populations.
Conclusions:
- Understanding DCM's complex pathways is crucial for managing diabetic cardiovascular risk.
- GLP-1 analogues and SGLT-2 inhibitors represent promising therapeutic avenues for DCM and associated heart failure.
- Further research into novel treatments is warranted to address the unmet medical needs in diabetic cardiovascular complications.
Abstract:
Diabetes mellitus (DM) and cardiovascular complications are two unmet medical emergencies that can occur together. The rising incidence of heart failure in diabetic populations, in addition to apparent coronary heart disease, ischemia, and hypertension-related complications, has created a more challenging situation. Diabetes, as a predominant cardio-renal metabolic syndrome, is related to severe vascular risk factors, and it underlies various complex pathophysiological pathways at the metabolic and molecular level that progress and converge toward the development of diabetic cardiomyopathy (DCM). DCM involves several downstream cascades that cause structural and functional alterations of the diabetic heart, such as diastolic dysfunction progressing into systolic dysfunction, cardiomyocyte hypertrophy, myocardial fibrosis, and subsequent heart failure over time. The effects of glucagon-like peptide-1 (GLP-1) analogues and sodium-glucose cotransporter-2 (SGLT-2) inhibitors on cardiovascular (CV) outcomes in diabetes have shown promising results, including improved contractile bioenergetics and significant cardiovascular benefits. The purpose of this article is to highlight the various pathophysiological, metabolic, and molecular pathways that contribute to the development of DCM and its significant effects on cardiac morphology and functioning. Additionally, this article will discuss the potential therapies that may be available in the future.
More Related Videos
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
10:07Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature
Published on: December 26, 2017
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:30Coronary Artery Disease I: Introduction
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:29Cardiomyopathy V: Interprofessional Care
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:20Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...